|  |  |  |  |
| --- | --- | --- | --- |
| **Bill Title and Description** | **Bill Number/Sponsor** | **Co-Sponsors** | **Status** |
| **Accelerating Kids’ Access to Care Act**  This bill would require state Medicaid programs to establish a process through which qualifying out-of-state providers may enroll as participating providers without undergoing additional screening requirements. Among other things, a qualifying provider must (1) serve minors, or adults whose condition began as a minor; and (2) have previously been screened for Medicare participation or for participation in the Medicaid program of the state in which the provider is located. | [H.R. 1509](https://www.congress.gov/bill/119th-congress/house-bill/1509?q=%7B%22search%22%3A%22hr1509%22%7D&s=1&r=1) Rep. Trahan (D-MA-13) | 15 D / 19 R | Introduced in House and referred to the Committee on Energy and Commerce on February 21, 2025. |
| [S. 752](https://www.congress.gov/bill/119th-congress/senate-bill/752/cosponsors) Sen. Grassley (R-IA) | 15 D / 15 R | Introduced in Senate and referred to the Committee on Finance on February 26, 2025. |
| **Innovation in Pediatric Drugs Act of 2025**  This bill would give the Food and Drug Administration (FDA) the authority to penalize drug companies that do not complete their pediatric studies and would increase funding for the Best Pharmaceuticals for Children Act (BPCA) NIH program. | No current House version. |  |  |
| [S. 705](https://www.congress.gov/bill/119th-congress/senate-bill/705?q=%7B%22search%22%3A%22s705%22%7D&s=3&r=1) Sen. Reed (D-RI) | 1 R | Introduced in the Senate and referred to the Senate Committee on Health, Education, Labor, and Pensions on February 25, 2025. |
| **Give Kids a Chance Act of 2025**  This bill would reauthorize the rare pediatric disease priority review voucher program until 2029, give the Food and Drug Administration (FDA) the resources needed to ensure the Pediatric Research Equity Act (PREA) studies get completed on time, and better allow researcher to study combinations of new cancer drugs. | [H.R. 1262](https://www.congress.gov/bill/119th-congress/house-bill/1262?s=7&r=1&q=%7B%22search%22%3A%22hr1262%22%7D) Rep. McCaul (R-TX-10) | 42 D/42 R | Introduced and referred to the House Committee on Energy and Commerce on February 12, 2025. |
| No current Senate version. |  |  |
|  |  |  |  |
|  |  |  |
|  |  |  |  |
|  |  |  |
|  |  |  |  |
|  |  |  |
|  |  |  |  |
|  |  |  |
|  |  |  |  |
|  |  |  |
|  |  |  |  |
|  |  |  |  |